Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Sarcoma × dabrafenib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 8 Glioma 3 Thyroid Neoplasms 2 Thyroid Carcinoma, Anaplastic 2 Neoplasm Metastasis 2 Multiple Myeloma 2 Glioblastoma 2 Astrocytoma 2 Thyroid cancer, follicular 1 Thyroid cancer, Hurthle cell 1 Thyroid Cancer, Papillary 1 Sarcoma 1 Oligodendroglioma 1 Neurofibromatosis 1 1 Neurofibroma, Plexiform 1 Neurocytoma 1 Neuroblastoma 1 Melanoma, Cutaneous Malignant 1 Lymphoma 1 Histiocytosis, Langerhans-Cell 1 Hematologic Neoplasms 1 Ganglioneuroma 1 Ganglioglioma 1 Fever 1 Differentiated Thyroid Cancer (DTC) 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1 Adenoma, Oxyphilic 1 Adenocarcinoma, Follicular 1 Adenocarcinoma 1

Interventions

Radiotherapy 9 Nivolumab 9 Magnetic Resonance Spectroscopy 9 pembrolizumab 8 Specimen Handling 8 Doxorubicin 8 Biopsy 7 X-Rays 6 Cyclophosphamide 6 Phantoms, Imaging 5 Ipilimumab 5 talimogene laherparepvec 4 Radiation 4 Nuclear Medicine Department, Hospital 4 selpercatinib 3 pazopanib 3 palbociclib 3 cabozantinib 3 Standard of Care 3 Sirolimus 3 Ifosfamide 3 Bevacizumab 3 ulixertinib 2 tipifarnib 2 tazemetostat 2 olaparib 2 liposomal doxorubicin 2 larotrectinib 2 ivosidenib 2 entrectinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03784014 2025-12-11

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Active not recruiting

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡